Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × OTHER × Nadolol × Clear all

Phase

Phase EARLY_PHASE1 1 Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Hemangioma, Capillary 1

Interventions

Cisplatin 857 Cyclophosphamide 804 Carboplatin 795 Radiotherapy 746 Bevacizumab 700 Gemcitabine 676 pembrolizumab 632 Docetaxel 629 Paclitaxel 614 Oxaliplatin 582 Capecitabine 541 Fluorouracil 485 Rituximab 475 Nivolumab 421 Dexamethasone 414 Etoposide 391 Doxorubicin 380 Irinotecan 374 Drug Therapy 326 Leucovorin 320 Cytarabine 294 Cetuximab 282 Lenalidomide 277 Trastuzumab 274 Pemetrexed 268 durvalumab 240 Filgrastim 240 Temozolomide 227 Prednisone 225 Magnetic Resonance Spectroscopy 223

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01010308 2021-08-19

Nadolol for Proliferating Infantile Hemangiomas

The Hospital for Sick Children

Phase 2 Completed

Hemangioma, Capillary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡